Home > Haematology > EBMT 2023 > Is ASCT a reasonable option in patients with invasive aspergillosis?

Is ASCT a reasonable option in patients with invasive aspergillosis?

Presented By
Dr Olaf Penack, Charité University Hospital of Berlin, Germany
EBMT 2023

Most patients with leukaemia and invasive aspergillosis (IA) undergoing allogeneic stem cell transplantation (ASCT) will benefit from this procedure. This was the main conclusion from a prospective study of the EBMT Infectious Diseases Working Party (IDWP). Thus, IA should not be considered as an absolute contraindication for ASCT, according to the authors.

“IA is common during the treatment of acute leukaemia,” said Dr Olaf Penack (Charité University Hospital of Berlin, Germany) [1]. “Since anti-fungal management has improved in recent years, it is interesting to examine the influence of IA on health outcomes in a recent cohort of patients with acute leukaemia and IA undergoing ASCT.” The current prospective study included 1,527 participants. The primary outcome was the 1-year non-relapse mortality.

The incidence of IA was 6.2% (n=95). A multivariate analysis demonstrated that the cumulative incidence of non-relapse mortality at  1-year post-ASCT was 16.9% in participants with IA and 11.4% in participants without IA (HR 1.9; P=0.02). The corresponding HRs for relapse-free survival and 1-year overall survival were 1.54 and 1.70, favouring the non-IA group over the IA group significantly.

    1. Penack O, et al. Influence of invasive aspergillosis during leukaemia treatment on survival after allogeneic stem cell transplantation: a prospective study of the EBMT infectious diseases working party. OS08-01, European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting, 23­–26 April 2023, Paris, France.


Copyright ©2023 Medicom Medical Publishers

Posted on